Life after BRCA1/2 testing: Family communication and support issues

Breast Disease

Volumn 27, Issue 1, 2007, Pages 127-136

  DeMarco, Tiffani A ^a   McKinnon, Wendy C ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

BRCA1; BRCA2; Breast and ovarian cancer; Family communication; Genetic testing; Support

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CONFIDENTIALITY; EMOTIONAL STRESS; ETHICAL DECISION MAKING; FAMILY COUNSELING; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL ETHICS; PATIENT AUTONOMY; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; SUPPORT GROUP;

EID: 35048861775     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2007-27108     Document Type: Article

References (65)

1. American Society of Clinical Oncology, American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility, J Clin Oncol 21 (2003), 2397-2406.
2. The American Society of Human Genetics Social Issues Subcommittee on Familial Disclosure, ASHG statement professional disclosure of familial genetic information, Am J Hum Genet 62 (1998), 474-483.
3. M.A. Bower, P. McCarthy Veach, D.M. Bartels et al., A survey of genetic counselors' strategies for addressing ethical and professional challenges in practice, J Genet Couns 11 (2002) 163-186.
4. The Breast Cancer Linkage Consortium, Cancer risks in BRCA2 mutation carriers, J Natl Cancer Inst 91 (1999), 1310-1316.
5. W. Burke, M. Daly, J. Garber et al., Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2, JAMA 278 (1997), 997-1003.
6. S. Clark, L. Bluman, N. Borstelmann et al., Patient motivation, satisfaction, and coping in genetic counseling and testing for BRCA1 and BRCA2, J Genet Counsel 9 (2000), 219-235.
7. E. Claes, G. Evers-Kiebooms, A. Boogaerts et al., Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients, Am J Med Genet A 116 (2003), 11-19.
8. J. Costalas, M. Itzen, J. Malick et al., Communication of BRCA1 and BRCA2 results to at-risk relatives: A cancer risk assessment program's experience, Am J Med Genet C Semin Med Genet 119 (2003), 11-18.
9. Council on Ethical and Judicial Affairs of the American Medical Association, Opinion E-2.131: Disclosure of familial risk in genetic testing: American Medical Association, code of medical ethics. Web Page Available at: Http://www.ama-assn. org/apps/pf↗w/ pf_online?f_n=resultLink&doc=policyfiles/HnE/ E-2.131.HTM&s_t=familial+risk&catg=AMA/HnE&catg=AMA/ BnGnC&catg=AMA/DIR&nth=1&st_p=0&nth=1, (Accessed January 16, 2007).
10. L. d'Agincourt-Canning, Experience of genetic risk: Disclosure and the gendering of responsibility, Bioethics 15 (2001), 231-247.
11. T.A. DeMarco, K. Tercyak, B. Peshkin et al., Risk communication and the family; assessing parental attitudes about communication BRCA1/2 test results to children, Presented at: 24th annual meeting of the National Society of Genetic Counselors Los Angeles, CA (November 10-15, 2005)
12. M. Dorval, A.F. Patenaude, K.A. Schneider et al., Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: Findings from p53 and BRCA1 testing programs, J Clin Oncol 18 (2000), 2135-2142.
13. D. Doukas, Genetic providers and the family covenant: Connecting individuals with their families, Genet Test 7 (2003), 315-321.
14. C. Dunkel-Schetter, Social support and cancer: Findings based on patient interviews and their interpretations, J Soc Issues 40 (1984), 77-98.
15. M.J. Esplen, J. Hunter, M. Leszcz et al., A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations, Cancer 101 (2004), 2327-2340.
16. Facing Our Risk of Cancer Empowered (FORCE) Web Page Available at www.facingourrisk.org, (Accessed 1/17/2007).
17. D. Ford, D.F. Easton, D.T. Bishop et al., Risks of cancer in BRCA1 mutation carriers. Breast cancer linkage consortium, Lancet 343 (1994), 692-695.
18. K. Forrest, S.A. Simpson, B.J. Wilson et al., To tell or not to tell: barriers and facilitators in family communication about genetic risk, Clin Genet 64 (2003), 317-326.
19. C. Gaff, V. Collins, T. Symes et al., Facilitating family communication about predictive genetic testing: Probands' perceptions, J Genet Couns 14 (2005), 133-140.
20. M.J. Galinsky and J.H. Schopler, Negative experiences in support groups, Social Work Health Care Special Issue 20 (1994), 77-95.
21. M. Gallo, D. Angst, K.A. Knafl et al., Parents sharing information with their children about genetic conditions, J Ped Health Care 19 (2005), 267-275.
22. Georgetown University Health Policy Institute: Consumer guides for getting and keeping health insurance. Available at http://www.healthinsuranceinfo.net (accessed 11/30/2006).
23. J. Green, M. Richards, F. Murton et al., Family communication and genetic counseling: The case of hereditary breast and ovarian cancer, J Genet Counsel 6 (1997), 45-60.
24. N. Hallowell, A. Arden-Jones, E.R. Foster et al., Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: Patterns, priorities and problems, Clin Genet 67 (2005), 492-502.
25. N. Hallowell and F. Murton, The value of written summaries of genetic consultations, Patient Edu Couns 35 (1998), 27-34.
26. C. Hughes, C. Lerman, M. Schwartz et al., All in the family: Evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results, Am J Med Genet 107 (2002), 143-150.
27. C.A. Hughes, Genetic testing for inherited breast-ovarian cancer susceptibility: The role of communication and personality characteristics, Ph.D. Dissertation, Howard University, 1997.
28. International Human Genome Sequencing Consortium, Initial sequencing and analysis of the human genome, Nature 409 (2001), 860-921.
29. C. Julian-Reynier, F. Eisinger, F. Chabal et al., Disclosure to the family of breast/ovarian cancer genetic test results: Patient's willingness and associated factors, J Med Genet 94 (2000), 8-13.
30. J. Karp, K.L. Brown, M.D. Sullivan et al., The prophylactic mastectomy dilemma: A support group for women at high genetic risk for breast cancer, J Genet Couns 8 (1999), 163-173.
31. B. Knoppers, C. Strom, E. Clayton et al., Professional disclosure of familial genetic information, Am J Hum Genet 62 (1998), 474-483.
32. L. M. Koehly, S.K. Peterson, B.G. Watts et al., A social network analysis of communication about hereditary nonpolyposis colorectal cancer genetic testing and family functioning, Cancer Epidemiol Biomarkers Prev 12 (2003), 304-313.
33. J. Kotsopoulos and S.A. Narod, Towards a dietary prevention of hereditary breast cancer, Cancer Causes Control 16 (2005), 125-138.
34. K. Landsbergen, C. Verhaak, F. Kraaimaat et al., Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients, Fam Cancer 4 (2005), 115-119.
35. C. Lerman, B.N. Peshkin, C. Hughes et al., Family disclosure in genetic testing for cancer susceptibility: Determinants and consequences, J Health Care Law Policy 1 (1998), 353-372.
36. A. Liede, B.Y. Karlan and S.A. Narod, Cancer risks for male carries of germline mutations in BRCA1 or BRCA2: A review of the literature, J Clin Oncol 22 (2004), 735-742.
37. A. Liede, K. Metcalfe, D. Hanna et al., Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling, Am J Hum Genet 67 (2000), 1494-1504.
38. Li-Fraumeni Syndrome, genetests.org Web Page Available at www.genetests.org, (Accessed January 17, 2007).
39. H.T. Lynch, T. Drouchard, H.F.A. Vasen et al., Genetic counseling in a Navajo hereditary nonpolyposis colorectal cancer kindred, Cancer 77 (1996), 30-35.
40. B. McGivern, J. Everett, G. Yager et al., Family communication about positive BRCA1 and BRCA2 genetic test results, Genet Med 6 (2004), 503-509.
41. W. McKinnon, S. Naud, A. Ashikaga et al., Results of an intervention for individuals and families with BRCA mutations: A model for providing medical updates and psychosocial support following genetic testing, J Genet Couns in press.
42. K.A. Metcalfe, A. Liede, M. Trinkaus et al., Evaluation of the needs of spouses of female carriers of mutations in BRCA1 and BRCA2, Clin Genet 62 (2002), 464-469.
43. A. Montazeri, S. Jarvandi, S. Haghighat et al., Anxiety and depression in breast cancer patients before and after participation in a cancer support group, Patient Educ Couns 45 (2001), 195-198.
44. S.A. Narod and K. Offit, Prevention and management of hereditary breast cancer, J. Clin Oncol 23 (2005), 1656-1663.
45. National Comprehensive Cancer Network, nccn.org. Web Page Available at http://www.nccn.org/professionals/physicians_gls/PDF/ genetics_screening.pdf, (Accessed January 17, 2007).
46. National Human Genome Research Institute, Genetic discrimination, genome.gov Web Page, Available at http://www.genome.gov/10002077#2, (Accessed 1/17/2007).
47. K. Offit and E. Groeger et al., The duty to warn a patient's family members about hereditary disease risks, JAMA 292 (2004), 1469-1473.
48. D.H. Olson, C.S. Russell and D.H. Sprehkle, Circumplex Model in Systemic Assessment and Treatment of Families, Haworth Press, New York, 1989, 7.
49. Parent Communication of BRCA1/2 Test Results to Child, www.genome.gov, Web Page, Available at http://www.genome.gov/
50. B.A. Peshkin, T.A. DeMarco, B.M. Brogan et al., BRCA1/2 testing: complex themes in result interpretation, J Clin Oncol 19 (2001), 2555-2565.
51. S.K. Peterson, B.G. Watts, L.M. Koehly et al., How families communicate about HNPCC testing: Findings from a qualitative study, Am J Med Genet 119c (2003), 78-86.
52. M. Richards, Families, kinship, and genetics, in: The Troubled Helix: Social and Psychological Implications of the New Human Genetics, T. Marteau and M. Richards, Cambridge University Press, Cambridge, 1996, pp. 249-251.
53. P.T. Rowley, Considering Family Covenants, Genet Test 7 (2003), 323.
54. K.A, Schneider, A.B. Chittenden, K.J. Branda et al., Ethical issues in cancer genetics: I 1) whose information is it? J Genet Counsel 15 (2006), 491-503.
55. J. Segal, M. Esplen, B. Toner et al., An investigation of the disclosure process and support needs of BRCA1 and BRCA2 carriers, Am J Med Genet A 125 (2004), 267-272.
56. S. Sobel, Do you Need to Know: Genetic testing for Huntington's Disease, in: The Shared Experience of Illness: Stories of patients, families, and their therapists, S. McDaniel, J. Hepworth, W. Doherty, eds, Basic Books, New York, 1997, pp. 173-183.
57. J. Speice, S. H. McDonald, P.T. Rowley et al., Family issues in a psychoeducation group for women with a BRCA mutation, Clin Genet 62 (2002), 121-127.
58. J.P Struewing, P. Hartage, S. Wacholder et al., The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews, N Engl J Med 336 (1997), 1401-1408.
59. K. Tercyak, B. Peshkin, T. DeMarco et al., Parent-child factors and their effect on communicating BRCA1/2 test results to children, Patient Educ Couns 47 (2002), 145-153.
60. K. Tercyak, C. Hughes D. Main et al., Parental communication of BRCA1/ 2 genetic test results to children, Patient Educ Couns 42 (2001), 213-224.
61. A. Trepanier, M. Ahrens, W. McKinnon et al., Genetic Cancer Risk Assessment and Counseling: Recommendations of the National Society of Genetic Counselors, J Genet Couns 13 (2004), 83-114.
62. I. van Oostrom, H. Meijers-Heijboer, H. Duivenvooden et al., Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: A prospective study, Clin Genet 71 (2007), 35-42.
63. M. Von Riper and W. McKinnon, Genetic testing for breast and ovarian cancer susceptibility: A family experience, J Midwifery Womens Health 49 (2004), 210-219.
64. A.J. Winzelberg, C. Classen, G.W. Alpers et al., Evaluation of an internet support group for women with primary breast cancer, Cancer 97 (2003), 1164-1173.
65. J.R. Zabora and E.D. Smith, Family dysfunction and the cancer patient: early recognition and intervention, Oncology 5 (1991), 31-35.